Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis

Nature Communications

Volumn 5, Issue , 2014, Pages

  Noda, Shinji ^a   Asano, Yoshihide ^a   Nishimura, Satoshi ^a,b,c   Taniguchi, Takashi ^a   Fujiu, Katsuhito ^a,b   Manabe, Ichiro ^a   Nakamura, Kouki ^a   Yamashita, Takashi ^a   Saigusa, Ryosuke ^a   Akamata, Kaname ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Tsuruta, Daisuke ^d   Trojanowska, Maria ^e   Nagai, Ryozo ^a,c   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AUTOANTIBODY; BLEOMYCIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DNA; HISTONE H3; HISTONE H4; KRUPPEL LIKE FACTOR 5; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FLI 1; FLI1 PROTEIN, HUMAN; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ANTIBODY; COLLAGEN; ENVIRONMENTAL FACTOR; GENETIC VARIATION; HETEROZYGOSITY; PATHOLOGY; PHENOTYPE; RODENT; SKIN DISORDER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BLOOD FLOW VELOCITY; CLINICAL FEATURE; COLLAGEN FIBRIL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG FIBROSIS; MALE; MARKER GENE; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN INDUCTION; PULMONARY VASCULAR DISEASE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSMISSION ELECTRON MICROSCOPY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD VESSEL; CASE CONTROL STUDY; DISEASE MODEL; FIBROBLAST; FIBROSIS; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN; TRANSGENIC MOUSE;

MUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; BLOOD VESSELS; CASE-CONTROL STUDIES; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FIBROBLASTS; FIBROSIS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LUNG; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN;

EID: 84923341300     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6797     Document Type: Article

References (70)

1. Varga, J. & Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557-567 (2007).
2. Leask, A. Signaling in fibrosis: Targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front. Biosci. (Elite Ed) 1, 115-122 (2009).
3. Ponticos, M. et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 60, 2142-2155 (2009).
4. Whitfield, M. L. et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl Acad. Sci. USA 100, 12319-12324 (2003).
5. Mori, T. et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J. Cell. Physiol. 181, 153-159 (1999).
6. Wang, Q. et al. Cooperative interaction of CTGF and TGF-b in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4, 4 (2011).
7. Asano, Y., Bujor, A. M. & Trojanowska, M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J. Dermatol. Sci. 59, 153-162 (2010).
8. Wang, Y., Fan, P. S. & Kahaleh, B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54, 2271-2279 (2006).
9. Dong, J. T. & Chen, C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell. Mol. Life Sci. 66, 2691-2706 (2009).
10. Takeda, N. et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254-265 (2010).
11. Fujiu, K., Manabe, I. & Nagai, R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J. Clin. Invest. 121, 3425-3441 (2011).
12. Shindo, T. et al. Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8, 856-863 (2002).
13. Spyropoulos, D. D. et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol. Cell. Biol. 20, 5643-5652 (2000).
14. Altorok, N., Almeshal, N., Wang, Y. & Kahaleh, B. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology (Oxford). PMID 24740406 (2014).
15. Altorok, N., Tsou, P. S., Coit, P., Khanna, D. & Sawalha, A. H. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann. Rheum. Dis.. PMID 24812288 (2014).
16. Luo, Y., Wang, Y., Wang, Q., Xiao, R. & Lu, Q. Systemic sclerosis: Genetics and epigenetics. J. Autoimmun. 41, 161-167 (2013).
17. Yamamoto, T. et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J. Invest. Dermatol. 112, 456-462 (1999).
18. Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961-972 (2011).
19. Van Beek, J. P., Kennedy, L., Rockel, J. S., Bernier, S. M. & Leask, A. The induction of CCN2 by TGFbeta1 involves Ets-1. Arthritis Res. Ther. 8, R36 (2006).
20. Nakerakanti, S. S., Kapanadze, B., Yamasaki, M., Markiewicz, M. & Trojanowska, M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J. Biol. Chem. 281, 25259-25269 (2006).
21. Perlish, J. S., Lemlich, G. & Fleischmajer, R. Identification of collagen fibrils in scleroderma skin. J. Invest. Dermatol. 90, 48-54 (1988).
22. Asano, Y. et al. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol. Cell. Biol. 29, 425-434 (2009).
23. Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989-2003 (2009).
24. Manetti, M., Guiducci, S., Ibba-Manneschi, L. & Matucci-Cerinic, M. Mechanisms in the loss of capillaries in systemic sclerosis: Angiogenesis versus vasculogenesis. J. Cell. Mol. Med. 14, 1241-1254 (2010).
25. Mugii, N. et al. Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. Rheumatology (Oxford) 48, 696-703 (2009).
26. Distler, O. et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ. Res. 95, 109-116 (2004).
27. Asano, Y. et al. Endothelial Fli1 deficiency impairs vascular homeostasis: A role in scleroderma vasculopathy. Am. J. Pathol. 176, 1983-1998 (2010).
28. Kundi, R. et al. Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: A role for CTGF. Cardiovasc. Res. 84, 326-335 (2009).
29. Bouros, D. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 165, 1581-1586 (2002).
30. Dorfmüller, P. et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol. 38, 893-902 (2007).
31. Chen, S. et al. CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: Implication in the pathogenesis of severe bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell. Mol. Physiol. 300, L330-L340 (2011).
32. Fujimoto, M. & Sato, S. B lymphocytes and systemic sclerosis. Curr. Opin. Rheumatol. 17, 746-751 (2005).
33. Lafyatis, R., O'Hara, C., Feghali-Bostwick, C. A. & Matteson, E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 56, 3167-3168 (2007).
34. Wang, K., Wei, G. & Liu, D. CD19: A biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1, 36 (2012).
35. Engel, P. et al. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3, 39-50 (1995).
36. Van Zelm, M. C. et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354, 1901-1912 (2006).
37. Sato, S., Hasegawa, M., Fujimoto, M., Tedder, T. F. & Takehara, K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165, 6635-6643 (2000).
38. Saito, E. et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J. Clin. Invest. 109, 1453-1462 (2002).
39. Barr, T. A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209, 1001-1010 (2012).
40. Khan, K. et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann. Rheum. Dis. 71, 1235-1242 (2012).
41. Giacomelli, R. et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J. Rheumatol. 23, 291-296 (1996).
42. Eferl, R. et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc. Natl Acad. Sci. USA 105, 10525-10530 (2008).
43. Sonnylal, S. et al. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 62, 1523-1532 (2010).
44. Medsger, T. A. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum. Dis. Clin. North. Am. 29, 255-273, vi (2003).
45. Krieg, T., Perlish, J. S., Fleischmajer, R. & Braun-Falco, O. Collagen synthesis in scleroderma: Selection of fibroblast populations during subcultures. Arch. Dermatol. Res. 277, 373-376 (1985).
46. Otsuka, A. et al. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J. Allergy Clin. Immunol. 133, 139-146 e110 (2014).
47. Shah, A. A., Rosen, A., Hummers, L., Wigley, F. & Casciola-Rosen, L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 62, 2787-2795 (2010).
48. Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152-157 (2014).
49. Noda, S. et al. Constitutive activation of c-Abl/protein kinase C-d/Fli1 pathway in dermal fibroblasts derived from patients with localized scleroderma. Br. J. Dermatol. 167, 1098-1105 (2012).
50. Tong, Z. et al. Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 50, 939-947 (2009).
51. Asano, Y. & Trojanowska, M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol. Cell. Biol. 29, 1882-1894 (2009).
52. Asano, Y., Czuwara, J. & Trojanowska, M. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREBbinding protein-associated factor-dependent acetylation. J. Biol. Chem. 282, 34672-34683 (2007).
53. Farina, G., Lafyatis, D., Lemaire, R. & Lafyatis, R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 62, 580-588 (2010).
54. Farina, G. et al. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann. Rheum. Dis. 68, 435-441 (2009).
55. Canty, E. G. & Kadler, K. E. Procollagen trafficking, processing and fibrillogenesis. J. Cell. Sci. 118, 1341-1353 (2005).
56. Corsi, A. et al. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. 17, 1180-1189 (2002).
57. Yeh, J. T. et al. Impaired skin wound healing in lumican-null mice. Br. J. Dermatol. 163, 1174-1180 (2010).
58. Ezura, Y., Chakravarti, S., Oldberg, A., Chervoneva, I. & Birk, D. E. Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J. Cell Biol. 151, 779-788 (2000).
59. Manno, R. L., Wigley, F. M., Gelber, A. C. & Hummers, L. K. Late-age onset systemic sclerosis. J. Rheumatol. 38, 1317-1325 (2011).
60. Overbeek, M. J. et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: A distinctive vasculopathy. Eur. Respir. J. 34, 371-379 (2009).
61. Hsu, E. et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 63, 783-794 (2011).
62. Shima, Y. et al. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Mod. Rheumatol. PMID 24533556 (2014).
63. Jordan, S. et al. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann. Rheum. Dis.. PMID 24442885 (2014).
64. Sato, S., Hasegawa, M. & Takehara, K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27, 140-146 (2001).
65. Kothapalli, D., Hayashi, N. & Grotendorst, G. R. Inhibition of TGF-betastimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle. FASEB J. 12, 1151-1161 (1998).
66. Oishi, Y. et al. Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab. 1, 27-39 (2005).
67. Shirasaki, F., Makhluf, H. A., LeRoy, C., Watson, D. K. & Trojanowska, M. Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 18, 7755-7764 (1999).
68. Wu, K. K. Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol. Biol. 338, 281-290 (2006).
69. Nishimura, S. et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J. Clin. Invest. 118, 710-721 (2008).
70. Nishimura, S. et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 119, e45-e56 (2012).